The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival

Estimates of benefits and harms of prophylactic use of aspirin in the general population

(2014) J. Cuzick et al.   ANNALS OF ONCOLOGY

Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer

(2014) Justin Bottsford-Miller et al.   CLINICAL CANCER RESEARCH

Pharmacological Regulation of Platelet Factors That Influence Tumor Angiogenesis

(2014) MengJie Yan et al.   SEMINARS IN ONCOLOGY

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies

(2012) M Mandalà et al.   BRITISH JOURNAL OF CANCER

Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance

(2012) A Radziwon-Balicka et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers

(2012) Jhanelle E. Gray et al.   CANCER

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow-Derived Cells

(2012) H. S. Kuznetsov et al.   Cancer Discovery

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

(2011) Robert A. Wolff et al.   CANCER

Increased Efficacy of Breast Cancer Chemotherapy in Thrombocytopenic Mice

(2011) M. Demers et al.   CANCER RESEARCH

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

(2011) Loic Ysebaert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Functional Divergence of Platelet Protein Kinase C (PKC) Isoforms in Thrombus Formation on Collagen

(2010) Karen Gilio et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

(2010) Erin M. Casey et al.   Journal of Thoracic Oncology

Enzastaurin

(2008) Yi-Bin Chen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS